D-0493-2017 Class II Terminated
FDA drug recall D-0493-2017 was initiated by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) on Jan 27, 2017 and is designated Class II. Reason for recall: Presence of Foreign Tablets/Capsules; possibility of Glipizide 10 mg tablets commingled The recall status is terminated (terminated Mar 15, 2019). Affected quantity: 58 UD100 Unit Dose Blister Cards of 10 (10 cards of 10 tablets each).
Recall details
- Product Type
- Drugs
- Report Date
- Mar 15, 2017
- Initiation Date
- Jan 27, 2017
- Termination Date
- Mar 15, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 58 UD100 Unit Dose Blister Cards of 10 (10 cards of 10 tablets each)
Product description
Mirtazapine Tablets, USP, 45 mg. Rx only, 100 Tablets (10 X 10). Manufactured by: Mylan Pharmaceuticals Inc, Morgantown, WV ---NDC 51079-088-20
Reason for recall
Presence of Foreign Tablets/Capsules; possibility of Glipizide 10 mg tablets commingled
Distribution pattern
Nationwide
Code information
Batch #3083289; Exp. Date 12/2018
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0493-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026